The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies
Abstract WHO-defined SARS-CoV-2 variants of concern (VOC) drive therapeutics and
vaccine development. The Omicron VOC is dominating the arena since November 2021, but …
vaccine development. The Omicron VOC is dominating the arena since November 2021, but …
A critical analysis of the use of cilgavimab plus tixagevimab monoclonal antibody cocktail (Evusheld™) for COVID-19 prophylaxis and treatment
D Focosi, A Casadevall - Viruses, 2022 - mdpi.com
Evusheld®(tixagevimab+ cilgavimab; AZD7442) was the first anti-Spike monoclonal
antibody (mAb) cocktail designed not only for treatment but also with pre-exposure …
antibody (mAb) cocktail designed not only for treatment but also with pre-exposure …
SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern
A Casadevall, D Focosi - The Journal of clinical …, 2023 - Am Soc Clin Investig
COVID-19 in immunocompromised hosts has emerged as a difficult therapeutic
management problem. Immunocompromised hosts mount weak responses to SARS-CoV-2 …
management problem. Immunocompromised hosts mount weak responses to SARS-CoV-2 …
Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment.
D Focosi, S McConnell, DJ Sullivan… - Drug Resistance Updates, 2023 - Elsevier
The mutation rate of the Omicron sublineage has led to baseline resistance against all
previously authorized anti-Spike monoclonal antibodies (mAbs). Nevertheless, in case more …
previously authorized anti-Spike monoclonal antibodies (mAbs). Nevertheless, in case more …
Development of therapeutic antibodies for the treatment of diseases
Z Wang, G Wang, H Lu, H Li, M Tang, A Tong - Molecular biomedicine, 2022 - Springer
Since the first monoclonal antibody drug, muromonab-CD3, was approved for marketing in
1986, 165 antibody drugs have been approved or are under regulatory review worldwide …
1986, 165 antibody drugs have been approved or are under regulatory review worldwide …
COVID-19 therapeutics
Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options
has been studied and deployed. Healthcare providers have multiple treatment approaches …
has been studied and deployed. Healthcare providers have multiple treatment approaches …
The efficacy of antivirals, corticosteroids, and mAbs as acute COVID treatments in reducing the incidence of long COVID: a Systematic Review and meta-analysis
G Sun, K Lin, J Ai, W Zhang - Clinical Microbiology and Infection, 2024 - Elsevier
Background Whether treatment during acute COVID results in protective efficacy against
long COVID incidence remains unclear. Objectives To assess the relationship between …
long COVID incidence remains unclear. Objectives To assess the relationship between …
The efficacy of antivirals, corticosteroids, and monoclonal antibodies as acute COVID-19 treatments in reducing the incidence of long COVID: a systematic review and …
G Sun, K Lin, J Ai, W Zhang - Clinical …, 2024 - clinicalmicrobiologyandinfection …
Background Whether treatment during acute COVID-19 results in protective efficacy against
long COVID incidence remains unclear. Objectives To assess the relationship between …
long COVID incidence remains unclear. Objectives To assess the relationship between …
Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants
Among the anti-Spike monoclonal antibodies (mAbs), the S-309 derivative sotrovimab was
the most successful in having the longest temporal window of clinical use, showing a high …
the most successful in having the longest temporal window of clinical use, showing a high …
WHO is recommending against the use of COVID-19 convalescent plasma in immunocompromised patients?
Since December 2019, SARS-CoV-2 is ravaging the globe, currently accounting for over
660 million infected people and more than 6.6 million deaths. As convalescent plasma had …
660 million infected people and more than 6.6 million deaths. As convalescent plasma had …